101 related articles for article (PubMed ID: 10620464)
21. Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancer.
De Placido S; Tramontana S; Ferrari E; De Matteis A; Lauria R; Perrone F; Bianco AR; Gallo C; Ricchi P; De Placido G; Pignata S;
Anticancer Res; 2000; 20(5C):4023-9. PubMed ID: 11268496
[TBL] [Abstract][Full Text] [Related]
22. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
[No Abstract] [Full Text] [Related]
23. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.
Chen YJ; Yuan CC; Chow KC; Wang PH; Lai CR; Yen MS; Wang LS
Gynecol Oncol; 2005 Apr; 97(1):110-7. PubMed ID: 15790446
[TBL] [Abstract][Full Text] [Related]
24. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery.
Lee SJ; Kim BG; Lee JW; Park CS; Lee JH; Bae DS
J Obstet Gynaecol Res; 2006 Feb; 32(1):99-106. PubMed ID: 16445534
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
Zanetta G; Fei F; Mangioni C
Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy for ovarian cancer.
Parmar MK; Sandercock J
N Engl J Med; 1996 May; 334(19):1268-9; author reply 1270. PubMed ID: 8606729
[No Abstract] [Full Text] [Related]
27. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
Ohie S; Udagawa Y; Kozu A; Komuro Y; Aoki D; Nozawa S; Moossa AR; Hoffman RM
Anticancer Res; 2000; 20(3B):2049-54. PubMed ID: 10928150
[TBL] [Abstract][Full Text] [Related]
28. Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer.
Hensley ML; Lebeau D; Leon LF; Venkatraman E; Waltzman R; Sabbatini P; Almadrones L; Chi D; Spriggs D
Gynecol Oncol; 2001 Jun; 81(3):485-9. PubMed ID: 11371143
[TBL] [Abstract][Full Text] [Related]
29. [Comparative pharmaco-economic analysis of docetaxel with cisplatin and cyclophosphamide with cisplatin in first-line chemotherapy of advanced ovarian cancer].
Gorbunova VA; Khokhlova SV; Komarova BP; Orel NF; Besova NS
Vopr Onkol; 2002; 48(6):695-9. PubMed ID: 12530266
[No Abstract] [Full Text] [Related]
30. Chemotherapy for ovarian cancer.
Lacave AJ; Peláez I; Palacio I
N Engl J Med; 1996 May; 334(19):1269-70. PubMed ID: 8606731
[No Abstract] [Full Text] [Related]
31. Mandating prospectively defined endpoints for ovarian cancer phase 2 trials: a strategy to improve the quality of gynecologic cancer clinical research.
Markman M
Gynecol Oncol; 2008 Sep; 110(3):275-7. PubMed ID: 18586312
[No Abstract] [Full Text] [Related]
32. First-line chemotherapy for ovarian cancer - the controversy continues.
Kaye SB
Br J Cancer; 2002 Oct; 87(8):813-4. PubMed ID: 12373592
[No Abstract] [Full Text] [Related]
33. [Treatment of platinum-resistant ovarian cancer].
Onishi Y; Nakamura T; Hatae M
Nihon Rinsho; 2004 Oct; 62 Suppl 10():554-9. PubMed ID: 15535307
[No Abstract] [Full Text] [Related]
34. Panel rejects calls for routine screening for ovarian cancer, cites role for paclitaxel.
Am J Hosp Pharm; 1994 Jun; 51(11):1381-2. PubMed ID: 7942870
[No Abstract] [Full Text] [Related]
35. Common epithelial cancer of the ovary (2).
Richardson GS; Scully RE; Nikrui N; Nelson JH
N Engl J Med; 1985 Feb; 312(8):474-83. PubMed ID: 3881673
[No Abstract] [Full Text] [Related]
36. [Cisplatin in ovarian cancer: how much and how long?].
Umbach GE; von Matthiessen H; Faber P
Dtsch Med Wochenschr; 1985 Mar; 110(12):472-6. PubMed ID: 3884309
[No Abstract] [Full Text] [Related]
37. [Update on gynecology].
Diéras V
Bull Cancer; 1998 Jan; 85(1):35-6. PubMed ID: 9752343
[No Abstract] [Full Text] [Related]
38. ICON2 trial. UK consensus statement on standard practice for chemotherapy in ovarian cancer.
Gore ME
Lancet; 1999 Feb; 353(9152):587-8. PubMed ID: 10029003
[No Abstract] [Full Text] [Related]
39. [Advanced ovarian cancer].
Guastalla JP; Talon A; Pinero O
Soins; 1995 Oct; (599):14, 16-9. PubMed ID: 8701348
[No Abstract] [Full Text] [Related]
40. Intraperitoneal chemotherapy for advanced epithelial ovarian cancer: many questions, much promise...
Gaillard S; Armstrong D
Oncology (Williston Park); 2011 Feb; 25(2):176, 178, 180. PubMed ID: 21456389
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
